News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,014 Results
Type
Article (62385)
Company Profile (450)
Press Release (632179)
Section
Business (183400)
Career Advice (3258)
Deals (33259)
Drug Delivery (106)
Drug Development (83896)
Employer Resources (181)
FDA (16063)
Job Trends (14874)
News (324449)
Policy (32105)
Tag
Academia (2915)
Alliances (47431)
Alzheimer's disease (1331)
Approvals (15971)
Artificial intelligence (143)
Bankruptcy (312)
Best Places to Work (11921)
Biotechnology (341)
Breast cancer (130)
Cancer (1167)
Cardiovascular disease (105)
Career advice (2751)
Cell therapy (271)
Clinical research (66103)
Collaboration (415)
Compensation (193)
COVID-19 (2711)
C-suite (102)
Data (1153)
Diabetes (162)
Diagnostics (6244)
Drug pricing (94)
Earnings (68756)
Employer resources (159)
Events (121725)
Executive appointments (308)
FDA (16623)
Funding (372)
Gene therapy (204)
GLP-1 (645)
Government (4734)
Healthcare (19821)
Infectious disease (2797)
Inflammatory bowel disease (119)
Interviews (624)
IPO (16084)
Job creations (3357)
Job search strategy (2264)
Layoffs (436)
Legal (7147)
Lung cancer (186)
Manufacturing (192)
Medical device (13369)
Medtech (13374)
Mergers & acquisitions (17291)
Metabolic disorders (449)
Neuroscience (1632)
NextGen Class of 2024 (7097)
Non-profit (4881)
Northern California (1487)
Obesity (256)
Opinion (236)
Patents (110)
People (52912)
Phase I (20658)
Phase II (29126)
Phase III (21627)
Pipeline (465)
Postmarket research (2719)
Preclinical (9139)
Radiopharmaceuticals (257)
Rare diseases (245)
Real estate (5910)
Regulatory (21619)
Research institute (2591)
Resumes & cover letters (530)
Southern California (1313)
Startups (3546)
United States (13881)
Vaccines (604)
Weight loss (204)
Date
Today (1)
Last 7 days (692)
Last 30 days (3648)
Last 365 days (37093)
2024 (34057)
2023 (41341)
2022 (52531)
2021 (57123)
2020 (55561)
2019 (48923)
2018 (36944)
2017 (33363)
2016 (33326)
2015 (38606)
2014 (31270)
2013 (26699)
2012 (28500)
2011 (28631)
2010 (26839)
Location
Africa (947)
Arizona (157)
Asia (40343)
Australia (7129)
California (3383)
Canada (1287)
China (262)
Colorado (151)
Connecticut (159)
Europe (93287)
Florida (455)
Georgia (120)
Illinois (379)
Indiana (187)
Kansas (98)
Maryland (614)
Massachusetts (2757)
Michigan (161)
Minnesota (276)
New Jersey (963)
New York (985)
North Carolina (768)
Northern California (1487)
Ohio (146)
Pennsylvania (842)
South America (1278)
Southern California (1313)
Texas (471)
Washington State (379)
695,014 Results for "ivy brain tumor center at the barrow neurological institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
The Ivy Brain Tumor Center at Barrow Neurological Institute announced a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma.
May 23, 2024
·
4 min read
Drug Development
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.
November 17, 2023
·
4 min read
Business
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical OfficerLeading Neuro-Oncologist Yoshie Umemura, MD, Joins Barrow Neurological Institute
The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute.
May 23, 2023
·
4 min read
Drug Development
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.
October 18, 2023
·
3 min read
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery MethodInnovative technique aims to bypass the most difficult barrier in brain cancer treatment
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI.
July 18, 2023
·
4 min read
Drug Development
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade GliomaStudy tests targeted agent, BDTX-1535, an EGFR inhibitor with brain-penetrant properties
The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.
November 6, 2023
·
3 min read
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade GliomaResults to be presented at 2023 ASCO Annual Meeting
The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is reporting initial results to the American Society of Clinical Oncology (ASCO) for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma, respectively.
June 2, 2023
·
3 min read
BioMidwest
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0 clinical trial of pamiparib in newly-diagnosed and recurrent glioblastoma in combination with radiation therapy.
September 10, 2022
·
3 min read
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized CareInnovative procedure offers doctors a scientific snapshot of tumor’s genetic evolution during experimental therapy
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.
September 7, 2022
·
3 min read
Press Releases
American Brain Tumor Association Names New President & Chief Executive Officer
November 19, 2024
·
3 min read
1 of 69,502
Next